Generic name: rucaparib camsylate 200mg
Dosage form: tablet, film coated
Medically reviewed on February 6, 2017.
Select patients for the treatment of advanced ovarian cancer with Rubraca based on the presence of a deleterious BRCA mutation (germline and/or somatic)[see Indications and Usage (1) and Clinical Studies (14)]. Information on the FDA-approved test for the detection of a tumor BRCA mutation in patients with ovarian cancer is available at: http://www.fda.gov/CompanionDiagnostics.
The recommended dose of Rubraca is 600 mg (two 300 mg tablets) taken orally twice daily with or without food.
Continue treatment until disease progression or unacceptable toxicity.
If a patient misses a dose of Rubraca, instruct the patient to take the next dose at its scheduled time. Vomited doses should not be replaced.
Dose Modifications for Adverse Reactions
To manage adverse reactions, consider interruption of treatment or dose reduction. Recommended dose reductions are indicated in Table 1.
|Starting Dose||600 mg twice daily (two 300 mg tablets)|
|First Dose Reduction||500 mg twice daily (two 250 mg tablets )|
|Second Dose Reduction||400 mg twice daily (two 200 mg tablets)|
|Third Dose Reduction||300 mg twice daily (one 300 mg tablet)|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Rubraca (rucaparib)
- Rubraca Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Support Group
- Pricing & Coupons
- En Español
- 0 Reviews
- Drug class: PARP inhibitors